Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Wei Yen Chan(The University of Sydney), Helen Rizos(Macquarie University), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(Westmead Hospital), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(University of California, San Francisco), Christian U. Blank(Oncode Institute), Jenny Lee(Blacktown & Mount Druitt Hospital), Maria Gonzalez(The University of Sydney), Alexander M. Menzies(The University of Sydney)
Cited by 22
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822